

# 1 Treatment of irritant contact dermatitis in healthcare settings during the COVID19 pandemic: 2 The emollient Dermol 500 exhibits virucidal activity against influenza A virus and SARS-CoV-2.

3  
4 *Christine T. Styles<sup>1</sup>, Michael Vanden Oever<sup>1</sup>, Jonathan Brown<sup>1</sup>, Sweta Rai<sup>2</sup>, Sarah Walsh<sup>2</sup>, Finola M. Ryan<sup>3,4</sup>,  
5 Wendy S. Barclay<sup>1</sup> and Rachel S. Edgar<sup>1\*</sup>*

6 <sup>1</sup>Department of Infectious Diseases, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK.

7 <sup>2</sup>Department of Dermatology, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS.

8 <sup>3</sup>Department of Occupational Health & Wellbeing, Jennie Lee House, King's College Hospital NHS Foundation Trust,  
9 London SE5 8AD, UK.

10 <sup>4</sup>Department of Targeted Intervention, University College London, Gower Street, London WC1E 6BT, UK.

11 \*Correspondence to Rachel S. Edgar; [rachel.edgar@imperial.ac.uk](mailto:rachel.edgar@imperial.ac.uk)

12

13 Key words: virucidal, antiviral, Dermol 500, antimicrobial emollient, influenza virus, SARS-CoV-2, COVID19,  
14 benzalkonium chloride (BAK), chlorohexidine dihydrochloride (CD), work-related contact dermatitis.

15

## 16 KEY MESSAGES

17

18 1. What is already known about this subject?

19 • Work-related contact dermatitis is a prominent issue among healthcare workers, and likely  
20 exacerbated by the enhanced hand hygiene and personal protective equipment required to control  
21 infection during the COVID19 pandemic.

22 • The antimicrobial lotion Dermol 500 is frequently prescribed as an emollient and soap substitute to  
23 help prevent and treat dermatitis, but its use during the COVID19 pandemic was not advised as its  
24 capacity to inactivate viruses was unknown.

25 2. What are the new findings?

26 • Increased incidence of irritant contact dermatitis was recorded amongst healthcare workers at King's  
27 College Hospital NHS Foundation Trust in 2020 compared to 2019.

28 • Dermol 500 lotion and its antimicrobial components, benzalkonium chloride (BAK) and chlorohexidine  
29 dihydrochloride (CD), exhibit virucidal activity against influenza A virus and SARS-CoV-2, the virus  
30 responsible for COVID19 pandemic.

31 3. How might this impact policy or clinical practice in the foreseeable future?

32 • Our results demonstrate that Dermol 500 can be safely used as a soap substitute to treat work-related  
33 contact dermatitis in clinical care settings during the COVID19 pandemic.

34 • Employers can meet their obligations under COSHH to eliminate workplace exposure to a harmful  
35 substance and substitute with an alternative product for hand hygiene.

36

## 37 ABSTRACT

38

39 **Objectives:** To investigate whether the antimicrobial emollient Dermol 500 and its active components,  
40 benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD), exhibit virucidal activity thus  
41 informing whether Dermol 500 is a suitable soap substitute for use during the COVID19 pandemic, to combat  
42 the increased incidence of work-related contact dermatitis in clinical settings that we report here.

43

44 **Methods:** Inactivation of influenza A virus and SARS-CoV-2 by Dermol 500 and the independent and  
45 combined virucidal activity of the Dermol 500 components BAK and CD was assessed by influenza A virus and  
46 SARS-CoV-2 infectivity assays. Viruses were treated with concentrations of BAK and CD comparable to  
47 Dermol 500, and lower, and infectivity of the viruses assessed by titration.

48

49 **Results:** Dermol 500 exhibits comparable virucidal activity to alcohol-based sanitisers against influenza A  
50 virus and SARS-CoV-2. In addition, the Dermol 500 components BAK and CD exhibit independent and  
51 synergistic virucidal activity against influenza A virus and SARS-CoV-2, the causative agent of COVID19.

52 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

53 **Conclusions:** The synergistic virucidal activity of the Dermol 500 components BAK and CD makes Dermol 500  
54 suitable as a soap substitute to treat and prevent work-related contact dermatitis in healthcare settings.

## 55 ABBREVIATIONS

56		
57	IAV:	Influenza A virus
58	SARS-CoV-2:	Severe acute respiratory syndrome coronavirus 2
59	PPE:	Personal protective equipment
60	COSHH:	Control of Substances Hazardous to Health Regulations
61	RIDDOR:	Reporting of Injuries, Diseases and Dangerous Occurrences Regulations
62	BAK:	Benzalkonium chloride
63	CD:	Chlorohexidine dihydrochloride
64	RT:	Room temperature
65	SFM:	Serum-free medium
66	CCV:	Canine coronavirus
67	HSV1:	Herpes simplex virus 1
68	HIV:	Human immunodeficiency virus
69	CMV:	Cytomegalovirus
70	RSV:	Respiratory syncytial virus
71	SARS-CoV-1:	Severe acute respiratory syndrome coronavirus 1


## 73 INTRODUCTION

74  
75 Hand hygiene is imperative in healthcare settings and hand washing with soap or use of alcohol-based hand  
76 sanitisers are advised worldwide to assist infection control<sup>1</sup>. However, such hand hygiene measures and use  
77 of personal protective equipment (PPE) such as gloves and masks can precipitate irritant contact dermatitis<sup>2</sup>.  
78 This skin condition is characterised by damage to the stratum corneum layer of the epidermis, resulting in  
79 cracked, dry and itchy skin with impaired barrier function, and advances to severe irritation and  
80 inflammation<sup>3</sup>. Following the development of dermatitis there is an elevated risk of bacterial colonisation  
81 and subsequent transmission to other healthcare workers or patients.

82  
83 Work-related contact dermatitis in healthcare professionals has been exacerbated by the infection control  
84 measures required during the COVID19 pandemic. 84.6% of surveyed Wuhan healthcare workers reported  
85 adverse skin reactions attributed to increased hand washing frequency<sup>4</sup>. Since March 2020, we have  
86 observed a sharp increase in NHS staff presenting with irritant hand dermatitis (Figure 1)<sup>5</sup>. Between 26<sup>th</sup>  
87 March – 6<sup>th</sup> May, 468 staff within King’s College Hospital NHS Foundation Trust presenting to a staff  
88 dermatology clinic were diagnosed with irritant hand dermatitis. For comparison, only 8 staff had this  
89 diagnosis recorded over the same time period in 2019 at the occupational health department of the hospital.  
90 A 9.5 fold increase in irritant contact dermatitis diagnoses has been observed overall in 2020 compared to  
91 2019 (Figure 1C), with significant increases in both occupational health walk-in cases and those diagnosed  
92 following management referral (Figures 1A and B).

93  
94 Although dermatitis is a prominent issue for healthcare workers, it is manageable with appropriate  
95 interventions<sup>3</sup>. Under UK health and safety law, legislation details that employers have a duty of care and  
96 statutory legal obligation to employees to minimise and avoid health problems caused by work, including  
97 development of skin conditions such as work-related dermatitis<sup>6</sup>. ‘The Control of Substances Hazardous to  
98 Health Regulations, (COSHH) 2002, (as amended)’ requires employers to identify substances that may be  
99 hazardous to health, assess risks and implement adequate control measures to control exposure and protect  
100 health<sup>7</sup>. Indeed, if the contact dermatitis is considered solely caused by work, it is reportable under the  
101 ‘Reporting of Injuries, Diseases and Dangerous Occurrences Regulations (RIDDOR) 2013’<sup>8,9</sup>. Prior to the  
102 COVID19 pandemic, the use of soap substitutes and emollients was advised to treat work-related contact  
103 dermatitis in healthcare workers by the Royal College of Physicians and other medical bodies<sup>2</sup>, meeting the  
104 COSHH requirement to eliminate exposure to the hazardous substance and substitute with an alternative.  
105 Notably, Dermol 500 lotion is usually prescribed as an antimicrobial emollient and soap substitute to aid skin  
106 conditions such as dermatitis<sup>10</sup>. However, due to a lack of evidence regarding whether Dermol 500 can  
107 inactivate virus particles, its use in clinical settings was discouraged during the COVID19 pandemic<sup>11</sup>.

**Figure 1. Comparative analysis of staff diagnosed with irritant contact dermatitis at King's College Hospital NHS Foundation Trust during 2019 and 2020.**



108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130

Dermol 500 contains the antimicrobial components benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD)<sup>10</sup>, which both have broad and well established antimicrobial activity<sup>12-13</sup>. This includes activity against the bacterial genera *Chlamydia*<sup>14</sup>, *Pseudomonas*<sup>15</sup>, *Streptococcus*<sup>16</sup> and *Staphylococcus*<sup>17</sup>, amongst others. BAK has been independently shown to exhibit virucidal activity against various enveloped viruses, including Canine coronavirus (CCV)<sup>18</sup>, herpes simplex virus 1 (HSV1)<sup>19</sup>, human immunodeficiency virus (HIV)<sup>19</sup> cytomegalovirus (CMV)<sup>14</sup> and respiratory syncytial virus (RSV)<sup>14</sup>. In addition, surface disinfectants where BAK is the principle active component have been shown to inactivate the SARS-CoV-1 coronavirus<sup>20</sup>. Virucidal activity has been demonstrated for the parental compound of CD (chlorohexidine), with alternative chlorohexidine salt form derivatives chlorohexidine gluconate and chlorohexidine acetate inactivating HIV and HSV-1<sup>19,21</sup>.

Synergistic or cumulative virucidal activity of BAK and CD within the context and concentration found in Dermol 500 lotion has not previously been reported. The purpose of this study was to assess the virucidal activity of Dermol 500 and its antimicrobial components BAK and CD against influenza A virus (IAV) and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus responsible for COVID19 disease.

## 131 METHODS

132

### 133 Cell culture

134 Madin-Darby Canine Kidney (MDCK) cells and VeroE6 cells were routinely cultured at 37°C with 5% CO<sub>2</sub> in  
135 Dulbecco's modified Eagle's Medium (DMEM; Gibco-Life Technologies) supplemented with 10% FCS, 1%  
136 penicillin/streptomycin and either Glutamax (MDCK) or NEAA (Vero E6)(Gibco-Life Technologies).  
137

### 138 Influenza infectivity assay

139 The influenza A virus used in this study was strain A/PR8/8/34 (H1N1), henceforth referred to as IAV. The  
140 virus was propagated in confluent MDCK flasks in the presence of TPCK-treated trypsin at 1 µg/ml  
141 (Worthingtons Bioscience) and serum-free DMEM containing 1% penicillin/streptomycin and 1% Glutamax  
142 (Gibco Life-Technologies)(SFM). MDCK cells were seeded in 6 well plates 24 to 72h prior to influenza  
143 infectivity assays.  
144

145 Due to their viscosity, Dermol 500 lotion and commercially available alcohol-based sanitisers were diluted  
146 1:1 to 50% concentration in SFM to allow for accurate pipetting. Virus was incubated with Dermol  
147 500/alcohol-based sanitisers at the final concentrations described, or with SFM alone as a control. The  
148 alcohol-based hand sanitisers assessed were: 1) Cuticura Original Hand Sanitiser, 2) Lifebuoy Hand Hygiene  
149 Sanitiser 3) Hygiene Vision Europe Ltd Hand Hygiene Sanitiser. Alternatively, virus was incubated with BAK  
150 and CD at the concentrations described (Sigma Aldrich; CD suspended in DMSO), culture medium alone or  
151 DMSO vehicle control (Supplementary Figure 1).  
152

153 Virus was incubated with the treatment for the stated times at either room temperature (RT) or 32°C  
154 (average skin temperature). Following incubation, SFM was added to the virus/treatment samples to a 10<sup>-1</sup>  
155 dilution then subject to 10-fold serial dilutions. The limit of detection was therefore 10<sup>1</sup> virus particles/mL.  
156 Due to adverse effects of BAK and CD on cultured *in vitro* cell lines the limit of detection for BAK and CD  
157 treatments between 0.05 - 0.1% was 10<sup>2</sup> virus particles/mL without filtration. Where noted, IAV was filtered  
158 to remove BAK/CD post-incubation using 15 mL Amicon Ultra-15 centrifugal filter with a 50,000 molecular  
159 weight cut off (UFC905008, Merck) and centrifugation (4000 x g, 10 min). Filtered virus was resuspended in  
160 SFM and serially diluted as above.  
161

162 Infectious virus was titred via standard plaque assay. Briefly, confluent MDCK cells were incubated with 1ml  
163 of virus dilutions for 1 hour at 37°C. Virus dilutions were aspirated and cells overlaid with 3ml SFM containing  
164 0.8% Avicel® (FMC BioPolymer), 0.14% BSA and TPCK-treated trypsin at 1 µg/ml (Worthingtons Bioscience).  
165 After 3 days, infected cells were fixed in PBS with 8-10% formalin, stained with 0.1% toluidine blue and viral  
166 plaque forming units (PFU) assessed.  
167

### 168 SARS-CoV-2 TCID<sub>50</sub> infectivity assay

169 The SARS-CoV-2 strain used in this study was SARS-CoV-2/England/IC19 and is henceforth referred to as  
170 'SARS-CoV-2'<sup>22</sup>. Vero E6 cells were seeded into 96-well plates in supplemented DMEM for confluence the  
171 next day. SARS-CoV-2 was incubated with either Dermol 500 or alcohol-based sanitiser diluted as for IAV  
172 above. Alternatively, BAK and CD diluted to 0.2% in assay diluent (DMEM, 0.3% BSA, 1X NEAA, 1X  
173 penicillin/streptomycin) were mixed with an equal volume of SARS-CoV-2 to a final concentration of 0.1%  
174 BAK and 0.1% CD. Virus was also mixed with assay diluent in the absence of Dermol 500, alcohol-based  
175 sanitisers or CD/BAK. After stated incubation period, neat sample was added to the first column of confluent  
176 Vero E6 cells and Log<sub>10</sub>/half-Log<sub>10</sub> dilution series immediately performed across the plate in assay diluent.  
177 Four technical replicates were performed for each sample. Plates were incubated for 5 days at 37°C before  
178 adding crystal violet stain (0.1% w/v) to live cells. Wells were scored for either an intact, stained cell sheet or  
179 the absence of cells due to virus-induced cytopathic effect. For each condition, the Spearman-Kärber method  
180 was used to calculate the 50% tissue culture infectious dose (TCID<sub>50</sub>) of the virus.  
181

### 182 Statistical analysis

183 All data was analysed using GraphPad Prism and presented as mean ± standard deviation (mean±SD). For  
184 each treatment condition, at least 2 independent biological replicates were performed.

185 **RESULTS**

186


187 **Dermol 500 exhibits virucidal activity against IAV and SARS-CoV-2 comparable to alcohol-based hand**  
 188 **sanitisers.**

189


190 To assess whether Dermol 500 emollient exhibits virucidal activity, we examined the capacity of IAV and  
 191 SARS-CoV-2 to infect cells following incubation with Dermol 500 (Figure 2). Dermol 500 lotion was diluted in  
 192 cell culture medium to allow for accurate pipetting, therefore could only be assessed at maximum 25% of its  
 193 original concentration. Even at this dilution, we observed a significant reduction in the amount of infectious  
 194 IAV after 30min incubation at skin temperature 32°C (~100-fold reduction in virus particles; Figure 2A), and  
 195 a similar decrease in SARS-CoV-2 infectivity after only 5min (Figure 2B). In parallel, we assessed the virucidal  
 196 activity of 3 commercially available alcohol-based hand sanitisers diluted equivalently. Importantly, Dermol  
 197 500 performed as well or better than these alcohol-based sanitisers at decreasing viral infectivity. The  
 198 virucidal effect of Dermol 500 was concentration-dependent, performing less well at a 12.5% dilution  
 199 (Supplementary Figure 2), indicating increased efficacy against viruses when Dermol 500 is used at its  
 200 intended concentration. In addition, increased incubation time correlated with enhanced reduction in  
 201 infectious virus.

**Figure 2. Dermol 500 lotion exhibits virucidal activity against IAV and SARS-CoV-2.**

**A)**



**B)**




(A) IAV was incubated with Dermol 500 or alcohol-based hand sanitisers at 25% final concentration, or medium-only control, for 5–120min at 32°C. Virus infectivity was assessed by plaque assay (n=2; mean±SD). 2-way ANOVA [treatment x time]: treatment \*\*\*\*P<0.0001, time P>0.05; multiple comparisons versus control: \*P<0.05, \*\*P<0.01, \*\*\*P<0.001. (B) SARS-CoV-2 was incubated with Dermol 500 or alcohol-based hand sanitisers at 25% final concentration for 5–60min, or assay diluent control for 60min, at 32°C. Virus infectivity was assessed by TCID<sub>50</sub> assay (n=2; mean±SD). 2-way ANOVA [treatment x time]: treatment \*\*\*\*P<0.0001, time \*\*P<0.0032; multiple comparisons versus control: \*P<0.05, \*\*P<0.01.

202

203 **The antimicrobial agents benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD) rapidly**  
 204 **inactivate IAV and SARS-CoV-2 at the concentrations found in Dermol 500 lotion.**  
 205

206 BAK and CD are considered the active antimicrobial agents in Dermol 500<sup>10</sup>, and alone have been reported  
 207 to exhibit some virucidal activity<sup>14 18-21</sup>. We tested their ability to inactivate IAV and SARS-CoV-2 in  
 208 combination, to determine whether they contribute to the virucidal activity of Dermol 500 lotion at their  
 209 intended concentration (Figure 3). Within 30 seconds of incubation with 0.1% BAK/0.1% CD the level of  
 210 infectious IAV decreased 100,000-fold, and by 3 minutes infectious virus had reached undetectable levels  
 211 (Figure 3A). For SARS-CoV-2, no virus-induced cytopathic effect was observed for samples incubated with  
 212 0.1% BAK/0.1% CD across all incubation time frames (10<sup>2</sup> TCID<sub>50</sub>/mL detection limit) indicating a >10,000-  
 213 fold reduction in virus infectivity within 0.5min of contact with BAK/CD, below the limit of detection. We  
 214 conclude that BAK and CD together are extremely potent virucidal agents against influenza and coronaviruses  
 215 at the concentrations found in Dermol 500 lotion.

**Figure 3. Benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD) exhibit rapid virucidal activity against IAV and SARS-CoV 2 at the concentration in Dermol 500.**




(A) IAV was incubated at 32°C with 0.1% BAK + 0.1% CD, or medium-only control, for 1-5min. IAV infectivity was assessed by plaque assay directly (unfiltered; 10<sup>2</sup> PFU/mL detection limit; n=2; mean±SD), or parallel samples were subject to filtration to remove BAK/CD prior to plaque assay (filtered; 10<sup>1</sup> PFU/mL detection limit; n=2; mean±SD). 2-way ANOVA [treatment x time]: unfiltered treatment \*\*P=0.0031, time P>0.05; filtered treatment \*\*\*P=0.0005, time P>0.05. (B) SARS-CoV-2 was incubated at RT with 0.1% BAK + 0.1% CD for either 0.5min (n=2), 10min (n=2) or 30min (n=4), or assay diluent control for 30min (n=4)(mean±SD). Virus infectivity was assessed by TCID<sub>50</sub> assay. No virus-induced cytopathic effect was observed for samples incubated with 0.1% BAK/0.1% CD across all incubation time frames (10<sup>2</sup> TCID<sub>50</sub>/mL detection limit). 2-tailed Mann-Whitney test: \*\*P=0.002.

216  
 217

218 **The antimicrobial agents BAK and CD independently inactivate IAV with different efficiencies, and act**  
 219 **synergistically to disrupt viral infectivity.**  
 220

221 We next investigated the virucidal activity of decreasing concentrations of BAK and CD, both in combination  
 222 and independently to further characterise their efficacy (Figure 4). Within a 30 second time frame, we  
 223 observed a significant decrease in IAV infectivity with the lowest concentration of BAK tested (0.0125%),  
 224 indicating that amounts could be reduced in future virucidal formulations. CD alone showed no significant  
 225 decrease in infectious virus over this time frame, but showed synergistic interaction with BAK by enhancing  
 226 its efficacy against IAV in a time- and temperature-dependent manner (Figure 4; Supplementary Figures 3  
 227 and 4). At skin temperature, CD starts to exert an independent virucidal effect at higher concentrations by 5  
 228 minutes, and by 30 minutes the lowest CD concentration has reduced IAV infectivity by 100-1000 fold.  
 229 0.0125% BAK/0.1% CD was the most efficient combination we tested, with IAV infectivity below detectable  
 230 levels within 30 seconds (Supplementary Figure 4).

**Figure 4. Viral inactivation by BAK and CD at concentrations less than 0.1%.**



231  
232

## DISCUSSION AND CONCLUSIONS

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Any employment that requires hand hygiene, exposure to irritants and PPE such as masks and gloves poses a risk of work-related skin disease, with irritant contact dermatitis the most common occupational inflammatory skin disease in Europe<sup>23</sup>. With the prominent worldwide focus on hand hygiene and PPE during the COVID19 pandemic, increased occurrence of work-related contact dermatitis will likely extend beyond clinical settings into commercial employment industries, particularly other key workers. Occupational dermatitis is a reportable disease under UK health and safety legislation<sup>6,8</sup>, and employers are legally obliged to minimise exposure to harmful substances and avoid health problems including skin conditions. The provision of emollients and soap substitutes, such as Dermol 500 lotion, are advised for treatment and prevention of dermatitis<sup>3</sup>, but not recommended currently due to a lack of evidence regarding their virucidal efficacy<sup>11</sup>. This study clearly demonstrates Dermol 500, and its antimicrobial components BAK and CD, exhibit robust virucidal activity against IAV and SARS-CoV-2, enabling its use against work-related contact dermatitis during the COVID19 pandemic.

Synonymous with the cumulative activity of BAK and CD against bacteria<sup>15</sup>, these compounds act synergistically to inactivate two different enveloped viruses, IAV and SARS-CoV-2. Extrapolating these results, we predict that Dermol 500 will be effective against other enveloped viruses, especially as both BAK and CD have been shown to independently inactivate the enveloped viruses HSV-1 and HIV<sup>19,21</sup>. Indeed, BAK has been shown to inactivate a broad range of enveloped viruses including CCV<sup>18</sup>, CMV<sup>14</sup>, RSV<sup>14</sup> and SARS-CoV-1<sup>20</sup>. Interestingly, 0.1% BAK is a component of many commercial nasal sprays, although listed as a preservative rather than an active ingredient<sup>24</sup>.

The mechanisms underpinning BAK and CD viral inactivation are poorly understood, and beyond the scope of this paper, but both have been commonly used antimicrobials since the 1950's. They are known to disrupt the physical integrity and biochemical functions of the lipid membranes of both gram-negative and gram-positive bacteria<sup>12,14,25-27</sup>. The synergistic activity of BAK and CD indicates they may inactivate viruses via

260 complementary mechanisms. Beyond disrupting lipid viral envelopes, BAK alone has been shown to  
261 inactivate various non-enveloped viruses including human coxsackie virus<sup>19</sup>, human adenoviruses<sup>28</sup> and  
262 enteroviruses<sup>14</sup>. However, BAK virucidal activity is less potent against non-enveloped viruses and requires  
263 longer incubation times to achieve viral inactivation<sup>14</sup>. BAK and CD virucidal activity could also encompass  
264 denaturation of viral glycoproteins required for attachment and entry. Indeed, chlorohexidine antimicrobial  
265 activity has been associated with inhibition of membrane bound proteins as well as coagulation and  
266 denaturation of cytoplasmic components, and may therefore access and denature viral proteins, especially  
267 in the presence of BAK<sup>12 29</sup>. The virucidal activity of these compounds and Dermol 500 lotion against non-  
268 enveloped viruses requires further study, but we predict they will be at least as efficacious as alcohol-based  
269 sanitisers, which inefficiently inactivate the majority of non-enveloped viruses<sup>1 30</sup>.

270

271 To conclude, this study confirms Dermol 500 lotion and its constituents inactivate SARS-CoV-2 and the  
272 common respiratory virus influenza A. This broad virucidal and antimicrobial activity of Dermol 500 emollient  
273 makes it a safe and efficacious soap substitute in healthcare settings to combat the adverse effects of  
274 frequent hand washing and PPE. Its use can prevent and treat work-related irritant contact dermatitis,  
275 helping curb the large increases in this skin condition seen during this pandemic. In turn, this will decrease  
276 instances of staff sickness absence, or restriction from clinical work due to skin disease, enhance the safe and  
277 timely delivery of clinical care, and benefit staff wellbeing.

278

### 279 **Contributors**

280 CTS designed the study, performed laboratory experiments, analysed the data, wrote and edited the  
281 manuscript. MVO and JB performed laboratory experiments and analysed the data. SR and SW provided  
282 clinical data and edited the manuscript. FMR proposed the research question, provided clinical data and  
283 edited the manuscript. WSB edited the manuscript and acquired funding. RSE designed the study, analysed  
284 the data, wrote and edited the manuscript, and acquired funding. All authors reviewed and approved the  
285 final manuscript.

286

### 287 **Funding**

288 This research was supported by a Wellcome Trust Sir Henry Dale Fellowship (208790/Z/17/Z) awarded to  
289 Rachel S. Edgar, funding awarded to Wendy Barclay by the Oak Foundation, and conducted as part of the  
290 G2P consortium funded by UKRI.

291

### 292 **Competing interests**

293 None declared.

294

### 295 **Patient consent for publication**

296 Not required.

297

### 298 **Ethics approval**

299 Not required

300

### 301 **Provenance and peer review**

302 Not commissioned; pending external peer review.

303

### 304 **Data availability statement**

305 Data is available on request.

306

### 307 **Acknowledgments**

308 We'd like to thank Dr Lucia Batty, Dr Lisa Curran and Mr James Kesson (King's College Hospital NHS  
309 Foundation Trust, London) for their assistance during the preparation of this manuscript, and Dr John O'Neill  
310 (MRC Laboratory of Molecular Biology, Cambridge) for helpful discussion.

311

312

313

314 **REFERENCES**

- 315
- 316 1. . WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean  
317 Care Is Safer Care. Geneva2009.
- 318 2. Smedley J, Williams S, Peel P, et al. Management of occupational dermatitis in healthcare  
319 workers: a systematic review. *Occup Environ Med* 2012;69(4):276-79. doi: 10.1136/oemed-  
320 2011-100315
- 321 3. Smedley J, Group OD, Group BD. Concise guidance: diagnosis, management and prevention of  
322 occupational contact dermatitis. *Clin Med (Lond)* 2010;10(5):487-90. doi:  
323 10.7861/clinmedicine.10-5-487 [published Online First: 2010/12/02]
- 324 4. Lin P, Zhu S, Huang Y, et al. Adverse skin reactions among healthcare workers during the  
325 coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. *Br J*  
326 *Dermatol* 2020;183(1):190-92. doi: 10.1111/bjd.19089 [published Online First: 2020/04/08]
- 327 5. Walsh SC, S. . Introduction of a hand dermatitis clinic to reduce occupational dermatoses during  
328 the covid-19 pandemic. *medRxiv* 2021020421250767 2021 doi:  
329 <https://doi.org/10.1101/2021.02.04.21250767> [published Online First: 08/02/2021]
- 330 6. Wrigglesworth F, Earl B. A guide to the Health and Safety at Work Act. Rev. ed. London: Industrial  
331 Society, 1978 1974.
- 332 7. Great Britain H, Safety Executive ap. Control of substances hazardous to health : the Control of  
333 Substances Hazardous to Health Regulations 2002 (as amended) : approved code of practice  
334 and guidance. Sixth edition. ed.
- 335 8. Great Britain H, Safety E. A guide to the Reporting of Injuries, Diseases and Dangerous  
336 Occurrences Regulations 1995, RIDDOR 95. Sudbury: HSE Books 1996.
- 337 9. Waclawski E. Disease reporting after the Reporting of Injuries, Diseases, and Dangerous  
338 Occurrence Regulations (1995) (RIDDOR) is revised. *Occup Med (Lond)* 2013;63(3):168-9.  
339 doi: 10.1093/occmed/kqs220 [published Online First: 2013/04/09]
- 340 10. Whitefield M. Effectiveness of a new antimicrobial emollient in the management of  
341 eczema/dermatitis. *J Dermatol Treat* 1998;9(2):103-09. doi: Doi  
342 10.3109/09546639809161381
- 343 11. British Society for Cutaneous Allergy BAoD. Update on occupational skin disease during the  
344 coronavirus pandemic: British Society for Cutaneous Allergy & British Association of  
345 Dermatologists; 2020 [updated 20/04/20. Available from:  
346 <https://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=66882020>.
- 347 12. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. *Clin*  
348 *Microbiol Rev* 1999;12(1):147-+. doi: Doi 10.1128/Cmr.12.1.147
- 349 13. Pereira BMP, Tagkopoulos I. Benzalkonium Chlorides: Uses, Regulatory Status, and Microbial  
350 Resistance. *Appl Environ Microb* 2019;85(13) doi: UNSP e00377-19  
351 10.1128/AEM.00377-19
- 352 14. Belec L, Tevi-Benissan C, Bianchi A, et al. In vitro inactivation of Chlamydia trachomatis and of a  
353 panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the  
354 spermicide benzalkonium chloride. *J Antimicrob Chemother* 2000;46(5):685-93. doi:  
355 10.1093/jac/46.5.685 [published Online First: 2000/11/04]
- 356 15. Richards RM, McBride RJ. Enhancement of Benzalkonium Chloride and Chlorhexidine Acetate  
357 Activity against Pseudomonas-Aeruginosa by Aromatic Alcohols. *J Pharm Sci-US*  
358 1973;62(12):2035-37. doi: DOI 10.1002/jps.2600621232
- 359 16. Mosca A, Russo F, Miragliotta G. In vitro antimicrobial activity of benzalkonium chloride against  
360 clinical isolates of Streptococcus agalactiae. *J Antimicrob Chemoth* 2006;57(3):566-68. doi:  
361 10.1093/jac/dki474

- 362 17. Castillo JA, Clapes P, Infante MR, et al. Comparative study of the antimicrobial activity of  
363 bis(Nalpha-caproyl-L-arginine)-1,3-propanediamine dihydrochloride and chlorhexidine  
364 dihydrochloride against Staphylococcus aureus and Escherichia coli. *J Antimicrob Chemother*  
365 2006;57(4):691-8. doi: 10.1093/jac/dkl012 [published Online First: 2006/02/10]
- 366 18. Saknimit M, Inatsuki I, Sugiyama Y, et al. Virucidal Efficacy of Physicochemical Treatments  
367 against Coronaviruses and Parvoviruses of Laboratory-Animals. *Exp Anim Tokyo*  
368 1988;37(3):341-45. doi: DOI 10.1538/expanim1978.37.3\_341
- 369 19. Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-  
370 enveloped viruses. *J Hosp Infect* 1998;38(4):283-95. doi: Doi 10.1016/S0195-6701(98)90077-  
371 9
- 372 20. Rabenau HF, Kampf G, Cinatl J, et al. Efficacy of various disinfectants against SARS coronavirus.  
373 *J Hosp Infect* 2005;61(2):107-11. doi: 10.1016/j.jhin.2004.12.023
- 374 21. Baqui AAMA, Kelley JJ, Jabra-Rizk MA, et al. In vitro effect of oral antiseptics on human  
375 immunodeficiency virus-1 and herpes simplex virus type 1. *J Clin Periodontol* 2001;28(7):610-  
376 16. doi: DOI 10.1034/j.1600-051x.2001.028007610.x
- 377 22. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine  
378 candidate induces high neutralizing antibody titers in mice. *Nat Commun* 2020;11(1):3523.  
379 doi: 10.1038/s41467-020-17409-9 [published Online First: 2020/07/11]
- 380 23. Diepgen TL. Occupational skin-disease data in Europe. *Int Arch Occup Environ Health*  
381 2003;76(5):331-8. doi: 10.1007/s00420-002-0418-1 [published Online First: 2003/04/12]
- 382 24. Ho CY, Wu MC, Lan MY, et al. In vitro effects of preservatives in nasal sprays on human nasal  
383 epithelial cells. *Am J Rhinol* 2008;22(2):125-9. doi: 10.2500/ajr.2008.22.3154 [published  
384 Online First: 2008/04/18]
- 385 25. Barrettbee K, Newbould L, Edwards S. The Membrane Destabilizing Action of the Antibacterial  
386 Agent Chlorhexidine. *Fems Microbiol Lett* 1994;119(1-2):249-53.
- 387 26. Cheung HY, Wong MMK, Cheung SH, et al. Differential Actions of Chlorhexidine on the Cell Wall  
388 of Bacillus subtilis and Escherichia coli. *Plos One* 2012;7(5) doi: ARTN e36659  
389 10.1371/journal.pone.0036659
- 390 27. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. *J Appl*  
391 *Microbiol* 2005;99(4):703-15. doi: 10.1111/j.1365-2672.2005.02664.x
- 392 28. Romanowski EG, Yates KA, Shanks RMQ, et al. Benzalkonium Chloride Demonstrates  
393 Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro. *J Ocul Pharmacol Th*  
394 2019;35(5):311-14. doi: 10.1089/jop.2018.0145
- 395 29. Denyer SP. Mechanisms of action of antibacterial biocides. *Int Biodeter Biodegr* 1995;36(3-  
396 4):227-45. doi: Doi 10.1016/0964-8305(96)00015-7
- 397 30. Golin AP, Choi D, Ghahary A. Hand sanitizers: A review of ingredients, mechanisms of action,  
398 modes of delivery, and efficacy against coronaviruses. *Am J Infect Control* 2020 doi:  
399 10.1016/j.ajic.2020.06.182 [published Online First: 2020/06/23]  
400